J&J's oral IL-23 pill Icotyde hits its Phase 3 goal in psoriatic arthritis

A pill that blocks the IL-23 receptor now has Phase 3 joint data. On 7 November, Johnson & Johnson reported that Icotyde (icotrokinra) met the primary endpoint of ICONIC-PsA 1 in adults with active psoriatic arthritis who had never had a biologic. The results were a late-breaking poster at ACR Convergence 2026.

What the trial showed

Patients took 200 mg of icotrokinra once a day or placebo. At week 16, 58% on the drug reached ACR20, the primary endpoint, against 41% on placebo. ACR50 was 29% versus 16% and ACR70 13% versus 5%, which J&J describes as numerically higher.

Get Tx Weekly every TuesdayThree-minute read. Free. One-click unsubscribe.

The skin numbers were sharper. Among patients with enough psoriasis at baseline to measure, 57% were clear or almost clear (IGA 0/1) at week 16, compared with 14% on placebo, and 37% reached PASI 90 against 6%. J&J flags those p-values as nominal.

By week 24, ACR20 had climbed to 69% and PASI 90 to 56% on the drug. Placebo patients still in the study switched to Icotyde at week 16. J&J says safety was consistent with what is already known, with no new signals. The release doesn't give patient numbers.

"These new findings underscore the potential of ICOTYDE to meaningfully improve outcomes in psoriatic arthritis" David M. Lee, MD, PhD, Global Immunology Therapeutic Area Head, Johnson & Johnson

Where it fits

Icotyde is a first-in-class oral peptide that targets the IL-23 receptor. It's already approved in the US for moderate-to-severe plaque psoriasis in adults and in children 12 and over who weigh at least 40 kg. It isn't approved in psoriatic arthritis, and the release doesn't say when J&J will file.

More data is on the way. ICONIC-PsA 2 is testing the drug in patients with and without prior biologic treatment, and separate trials are running in ulcerative colitis (ICONIC-UC) and Crohn's disease (ICONIC-CD). The molecule was jointly discovered with Protagonist Therapeutics; J&J holds exclusive worldwide rights from Phase 2 onwards, according to the release.

The bigger picture

Oral IL-23 is turning into a race. Two weeks ago, Gilead paid $1.275 billion upfront for PepStar's oral IL-23R drug, which is still in Phase 1, with an all-oral IBD combination in mind. J&J is already selling its pill and is now stacking up indications. The prize is patients who would rather swallow a tablet than inject a biologic, across skin, joints and gut.

What it means for hiring

Moving one brand from dermatology into rheumatology means new prescribers, new field teams and new medical affairs relationships. Rheumatology MSLs and KAMs with IL-23 experience should be in demand.
With several companies chasing oral IL-23, people who have launched an oral immunology product against injectables are a scarce and valuable profile.
Multi-indication programmes in skin, joints and IBD need clinical leaders who can run parallel Phase 3s. We'd expect I&I clinical development heads to stay hard to hire.

Share Ask Harry about this →